These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 23098502)

  • 1. Oral etoposide for platinum-resistant and recurrent epithelial ovarian cancer: a study by the Anatolian Society of Medical Oncology.
    Kucukoner M; Isikdogan A; Yaman S; Gumusay O; Unal O; Ulas A; Elkiran ET; Kaplan MA; Ozdemir N; Inal A; Urakci Z; Buyukberber S
    Asian Pac J Cancer Prev; 2012; 13(8):3973-6. PubMed ID: 23098502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of low-dose oral etoposide treatment in patients with recurrent and platinum-resistant epithelial ovarian cancer.
    Bozkaya Y; Doğan M; Umut Erdem G; Tulunay G; Uncu H; Arık Z; Demirci U; Yazıcı O; Zengin N
    J Obstet Gynaecol; 2017 Jul; 37(5):649-654. PubMed ID: 28325092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunomodulatory therapy in refractory/recurrent ovarian cancer.
    Chen CY; Lai CH; Yang LY; Tang YH; Chou HH; Chang CJ; Lin CT
    Taiwan J Obstet Gynecol; 2015 Apr; 54(2):143-9. PubMed ID: 25951718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival outcomes of recurrent epithelial ovarian cancer: experience from a Thailand northern tertiary care center.
    Jansaka N; Suprasert P
    Asian Pac J Cancer Prev; 2014; 15(24):10837-40. PubMed ID: 25605186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Weekly topotecan for recurrent ovarian, fallopian tube and primary peritoneal carcinoma: tolerability and efficacy study--the Israeli experience.
    Safra T; Berman T; Yachnin A; Bruchim I; Meirovitz M; Barak F; Atlas I; Levy T; Rosengarten OS
    Int J Gynecol Cancer; 2013 Mar; 23(3):475-80. PubMed ID: 23435437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Salvage chemotherapy in recurrent platinum-resistant or refractory epithelial ovarian cancer with Carboplatin and distearoylphosphatidylcholine pegylated liposomal Doxorubicin (lipo-dox®).
    Khemapech N; Oranratanaphan S; Termrungruanglert W; Lertkhachonsuk R; Vasurattana A
    Asian Pac J Cancer Prev; 2013; 14(3):2131-5. PubMed ID: 23679331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study.
    Rose PG; Blessing JA; Mayer AR; Homesley HD
    J Clin Oncol; 1998 Feb; 16(2):405-10. PubMed ID: 9469322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant, recurrent, pre-treated ovarian cancer - Results of the PACOVAR-trial.
    Dinkic C; Eichbaum M; Schmidt M; Grischke EM; Gebauer G; Fricke HC; Lenz F; Wallwiener M; Marme F; Schneeweiss A; Sohn C; Rom J
    Gynecol Oncol; 2017 Aug; 146(2):279-284. PubMed ID: 28528917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective evaluation of weekly topotecan in recurrent platinum-resistant epithelial ovarian cancer.
    Le T; Hopkins L; Baines KA; Rambout L; Fung-Kee-Fung M
    Int J Gynecol Cancer; 2008; 18(3):428-31. PubMed ID: 17692088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity and safety of oral etoposide in pretreated patients with metastatic or recurrent thymic epithelial tumors (TET): A single-institution experience.
    Bluthgen MV; Boutros C; Fayard F; Remon J; Planchard D; Besse B
    Lung Cancer; 2016 Sep; 99():111-6. PubMed ID: 27565923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrospective comparative study of irinotecan and pegylated liposomal doxorubicin for platinum-resistant or -refractory epithelial ovarian and primary peritoneal carcinoma.
    Ichikawa R; Torii Y; Oe S; Kawamura K; Kato R; Hasegawa K; Udagawa Y
    Arch Gynecol Obstet; 2014 Nov; 290(5):979-84. PubMed ID: 24798935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of weekly topotecan in the treatment of heavily pretreated recurrent epithelial ovarian and primary peritoneal cancer: the Kaohsiung Chang Gung experience.
    Hu CF; Ou YC; Fu HC; Chang Chien CC; Tsai CC; Wu CH; Lin H
    Taiwan J Obstet Gynecol; 2015 Feb; 54(1):43-7. PubMed ID: 25675918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral etoposide for refractory or recurrent epithelial ovarian cancer.
    Thavaramara T; Tangjitgamol S; Manusirivithaya S; Leelahakorn S
    J Med Assoc Thai; 2009 Nov; 92(11):1397-405. PubMed ID: 19938729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pazopanib based oral metronomic therapy for platinum resistant/refractory epithelial ovarian cancer: A phase II, open label, randomized, controlled trial.
    Sharma A; Singh M; Chauhan R; Malik PS; Khurana S; Mathur S; Kumar S; Sreenivas V; Kumar L
    Gynecol Oncol; 2021 Aug; 162(2):382-388. PubMed ID: 34088513
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II study of lenalidomide in platinum-sensitive recurrent ovarian carcinoma.
    Selle F; Sevin E; Ray-Coquard I; Mari V; Berton-Rigaud D; Favier L; Fabbro M; Lesoin A; Lortholary A; Pujade-Lauraine E
    Ann Oncol; 2014 Nov; 25(11):2191-2196. PubMed ID: 25210017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Daily low-dose oral etoposide for recurrent epithelial ovarian cancer after platinum-based therapy.
    Moosavi AS; Gilani MM; Tehranian A; Esfahani JK
    J Obstet Gynaecol; 2004 Apr; 24(3):292-3. PubMed ID: 15203631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased dose single-agent gemcitabine in platinum-taxane resistant metastatic ovarian cancer.
    Kodaz H; Hacibekiroglu I; Turkmen E; Erdogan B; Elpen C; Uzunoglu S; Cicin I
    Tumori; 2015; 101(1):36-40. PubMed ID: 25702671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intraperitoneal chemotherapy for recurrent epithelial ovarian cancer is feasible with high completion rates, low complications, and acceptable patient outcomes.
    Skaznik-Wikiel ME; Lesnock JL; McBee WC; Beriwal S; Zorn KK; Richard SD; Krivak TC; Edwards RP
    Int J Gynecol Cancer; 2012 Feb; 22(2):232-7. PubMed ID: 22080886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral cyclophosphamide in recurrent ovarian cancer.
    Handolias D; Quinn M; Foo S; Mileshkin L; Grant P; Dutu G; Rischin D
    Asia Pac J Clin Oncol; 2016 Mar; 12(1):e154-60. PubMed ID: 23718870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Weekly cisplatin and oral etoposide as treatment for relapsed epithelial ovarian cancer.
    Meyer T; Nelstrop AE; Mahmoudi M; Rustin GJ
    Ann Oncol; 2001 Dec; 12(12):1705-9. PubMed ID: 11843248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.